State Department spokeswoman Jen Psaki says. As a result of the review directed by President Obama, we have decided to maintain our relationship with the Egyptian government, while recalibrating our assistance to Egypt to best advance our interests, Psaki said in a prepared statement. Secretary of State John Kerry addressed the change in military assistance while traveling in Kuala Lumpur, Malaysia, October 10. Kerry told journalists that the United States has been having constant conversations regarding the way forward in Egypt and that the interim government fully understands the U.S. commitment to the success of the Egyptian government. And by no means is this a withdrawal from our relationship or severing of our serious commitment to helping the government meet those goals, Kerry added. In addition, were going to continue to support areas that directly benefit the Egyptian people education, private sector development, he added. We want to make sure that the road map results in a constitution that recognizes universal human rights, that respects minorities, that brings people to the table in an inclusive way, and ultimately results in free and fair elections, Kerry said. In his discussions with the interim government, Kerry said, the Egyptian leaders have insisted that is exactly the road map they are on and intend to achieve. He added that the United States is holding back a certain amount of assistance that is not relevant to the immediate needs of the government or for security. The reduction in some assistance follows the ouster of President Mohamed Morsy in July and a crackdown on several political groups, including the Muslim Brotherhood. The United States is withholding delivery of four F-16 fighter jet aircraft, tank kits for the M1A1 main battle tank, Harpoon anti-ship missiles and 10 Apache attack helicopters, a senior U.S.
United States Reduces Some Military Assistance to Egypt
Food and Drug Administration has granted approval of the generic equivalent to TOBI(R) (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI(R) had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012. Teva’s Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, including our ability to develop, manufacture, market and sell biopharmaceutical products, competition for our innovative products, especially COPAXONE(R) (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our specialty, including innovative, R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S.